Development of Rationally Designed Cancer Vaccines Using Protein-like Polymers (PLPs)
使用类蛋白聚合物 (PLP) 开发合理设计的癌症疫苗
基本信息
- 批准号:10457246
- 负责人:
- 金额:$ 5.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-05-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdjuvantAffectAgonistAmidesAmino AcidsAntigen-Presenting CellsAntigensAntitumor ResponseArchitectureAreaAutoimmunityCT26Cancer VaccinesCell ProliferationCellsCharacteristicsChemistryClinicalColon CarcinomaCombination immunotherapyComplexCross PresentationDataDevelopmentDisulfide LinkageDrug KineticsEstersExhibitsFormulationGenerationsHarvestHeterophile AntigensHigh Pressure Liquid ChromatographyHuman papillomavirus 16HydrophobicityImmuneImmune responseImmunityIncubatedKineticsLabelLengthLibrariesMalignant NeoplasmsMediatingMethodologyMethodsModelingMolecular WeightMusNeoplasm TransplantationNucleic AcidsOncoproteinsOvalbuminPatientsPeptidesPolymersPost-Translational Protein ProcessingProductionPropertyProteinsProteolysisReactionResistanceRiskSILV geneSTING agonistsSideSignal TransductionSiteSomatic MutationStructureStructure-Activity RelationshipSubunit VaccinesSystemT-LymphocyteTestingTherapeuticTimeTissuesTransgenic OrganismsTreatment ProtocolsTumor AntigensTumor BurdenTumor ImmunityVaccinationVaccinesVertebral columnanti-PD-1/PD-L1anti-PD-L1 antibodiesanti-canceranti-tumor immune responsebasecancer cellcancer immunotherapycentral tolerancecombinatorialcopolymercytokinedensitydesigndisulfide bondearly phase clinical trialeffective therapyeffectiveness evaluationefficacy testingexperimental studygp100 Antigenimmunogenicimmunoregulationimprovedin vitro Assayin vivoinsightinterestmelanomamelanoma-associated antigennanoparticlenanotechnology platformneoantigensnovelperipheral tolerancephysical propertypolymerizationpreservationpreventrational designsmall moleculespatiotemporalsynergismtargeted deliverythree dimensional structuretreatment optimizationtumoruptakevaccine efficacyvaccine formulation
项目摘要
PROJECT SUMMARY
The utilization of tumor antigens, which are antigenic peptides expressed in cancer cells as a result of random
somatic mutations, for the development of patient-specific therapeutic cancer vaccines has been an area of
intense interest. However, significant challenges remain in safely and efficiently delivering subunit vaccine
components for the elicitation of robust antitumor immune responses. To overcome these challenges, this
proposal utilizes a new methodology for protecting active peptides from proteolysis for the sustained delivery of
tumor antigens in conjunction with immunomodulatory compounds as rationally designed cancer vaccines. This
approach packages peptides together as high-density brush polymers, which results in the introduction of unique
characteristics with significant advantages over conventional attempts to utilize peptides as therapeutics. These
include increased resistance to proteolysis and improved pharmacokinetic profiles, while maintaining strong
bioactivity and cell uptake. This peptide packaging method is termed Protein-Like Polymers (PLPs) due to its
globular, peptide-based structure assembled around a hydrophobic synthetic polymer core, displaying active
amino acids for recognition and function in a sequence-controlled manner. PLPs are modular in terms of payload,
able to be conjugated with defined proportions of peptides, small molecules, and nucleic acids. Further
modifications of PLPs can confer additional properties including tissue targeting, site-specific cargo release, and
changes in packing density. The PLP nanoplatform demonstrates that compounds arranged in unique 3-
dimensional structures exhibit properties exclusive to that configuration, providing new avenues for biomolecule
delivery. For this proposal, PLPs will be used to overcome inherent difficulties associated with utilizing tumor
antigens as cancer vaccines, namely by preventing their degradation, enabling targeted delivery, and allowing
proportion-defined multivalent display of dissimilar antigens with immunostimulatory compounds.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Max Wang其他文献
Max Wang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Max Wang', 18)}}的其他基金
Development of Rationally Designed Cancer Vaccines Using Protein-like Polymers (PLPs)
使用类蛋白聚合物 (PLP) 开发合理设计的癌症疫苗
- 批准号:
10152127 - 财政年份:2021
- 资助金额:
$ 5.03万 - 项目类别:
Development of Rationally Designed Cancer Vaccines Using Protein-like Polymers (PLPs)
使用类蛋白聚合物 (PLP) 开发合理设计的癌症疫苗
- 批准号:
10616538 - 财政年份:2021
- 资助金额:
$ 5.03万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 5.03万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 5.03万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 5.03万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 5.03万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 5.03万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 5.03万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 5.03万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 5.03万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 5.03万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 5.03万 - 项目类别: